GlassScriptPhysician profile
Anshul Kumar
NPI 1558674226
$5,326.73
in general payments reported to CMS, 2019-2025
29 companies · $1,284 in 2025
The $1,284 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $439 · 2020: $450 · 2021: $340 · 2022: $712 · 2023: $902 · 2024: $1,200 · 2025: $1,284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,209 · Education: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,209.24 |
| Education | $176.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $811.09 | 2019-2025 | Lokelma, Farxiga |
| Opko Pharmaceuticals, LLC | $446.24 | 2019-2025 | Rayaldee |
| Vifor Pharma, INC. | $415.32 | 2019-2023 | Veltassa, Korsuva |
| Novartis Pharmaceuticals Corporation | $349.97 | 2019-2025 | |
| Fresenius USA Marketing, INC. | $337.60 | 2019-2025 | Velphoro, Velphoro |
| Ani Pharmaceuticals, INC. | $329.89 | 2024-2025 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $322.49 | 2022-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $272.62 | 2019-2022 | |
| Ardelyx, INC. | $235.29 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Akebia Therapeutics INC | $230.80 | 2019-2025 | Vafseo, Auryxia |
| Horizon Therapeutics Plc | $228.88 | 2020-2023 | Krystexxa |
| Travere Therapeutics, INC. | $226.88 | 2022-2025 | Filspari |
| Aurinia Pharma U.S., INC. | $215.25 | 2023-2024 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $199.93 | 2020-2025 | Acthar, Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $169.66 | 2022-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $105.42 | 2020-2025 | Repatha, Repatha |
| Vantive US Healthcare LLC | $82.73 | 2025 | Renal - Pd |
| Nxstage Medical, INC. | $61.92 | 2022 | |
| Glaxosmithkline, LLC. | $59.00 | 2023-2025 | Benlysta |
| Daiichi Sankyo INC. | $46.43 | 2022-2023 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.84 | 2025 | Jardiance |
| Mozarc Medical US LLC | $25.00 | 2025 | Argyle |
| Covidien LP | $23.72 | 2019 | |
| Inari Medical, INC. | $19.61 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Apellis Pharmaceuticals, INC. | $19.41 | 2025 | Empaveli |
| Ultragenyx Pharmaceutical INC. | $14.84 | 2023 | Crysvita |
| Janssen Pharmaceuticals, INC | $13.16 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $12.06 | 2019 | |
| Pfizer INC. | $11.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anshul Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.